AWH:NYE-Aspira Women's Health Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 2.89

Change

0.00 (0.00)%

Market Cap

USD 0.30B

Volume

0.53M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas. Address: Building III, Austin, TX, United States, 78738

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

N/A

USD167.05B 45.25 26.57
DHR Danaher Corporation

N/A

USD146.96B 51.43 31.30
DHR-PA Danaher Corporation

N/A

USD130.15B 247.45 N/A
PHG Koninklijke Philips N.V

N/A

USD40.86B 35.12 15.54
A Agilent Technologies, Inc

N/A

USD30.12B 43.40 26.03
IQV IQVIA Holdings Inc

N/A

USD28.94B 222.33 20.78
MTD Mettler-Toledo International I..

N/A

USD23.37B 43.04 29.78
LH Laboratory Corporation of Amer..

N/A

USD17.63B 49.74 17.05
DGX Quest Diagnostics Incorporated

N/A

USD15.00B 19.82 12.69
PKI PerkinElmer, Inc

N/A

USD13.40B 44.85 24.62

ETFs Containing AWH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -97.44% 6% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.44% 6% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 8.69% N/A N/A 77% C+
Dividend Return 3.52% N/A N/A 74% C
Total Return 12.21% N/A N/A 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 31.64% N/A N/A 19% F
Risk Adjusted Return 38.61% N/A N/A 55% F
Market Capitalization 0.30B 25% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.10 94% A 48% F
Price/Book Ratio 37.22 12% F 1% F
Price / Cash Flow Ratio -23.19 95% A 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -142.92% 10% F 3% F
Return on Invested Capital -163.73% 5% F 1% F
Return on Assets -59.53% 10% F 0% N/A
Debt to Equity Ratio 12.58% 79% C+ 86% B
Technical Ratios  
Short Ratio 9.57 16% F 7% F
Short Percent 11.89% 17% F 34% F
Beta 3.26 5% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector